Moffit Cancer Center received FDA approval for a second dose of CAR-T therapy for ovarian cancer patient with clinical activity.
Anixa Biosciences' collaborator, Moffit Cancer Center, received FDA approval for an individual patient IND to administer a second dose of its CAR-T therapy for ovarian cancer. This follows a patient showing clinical activity after initial treatment, even though tumor size initially increased. Principal investigator Dr. Robert Wenham stated that the patient has remained off new therapy for several months with no new disease.
July 23, 2024
3 Articles